Functional Genomic Core

$68,763P30FY2025CANIH

Duke University, Durham NC

Investigators

Linked publications, trials & patents

Paper 39605338 Paper 39416087 Paper 39320053 Paper 39307527 Paper 39253977 Paper 39238136 Paper 39227594 Paper 39176091 Paper 39146842 Paper 39133651 Paper 39083560 Paper 39075068 Paper 39034366 Paper 39014162 Paper 38976158 Paper 38935899 Paper 38886328 Paper 38886323 Paper 38871555 Paper 38860607 Paper 38826146 Paper 38798534 Paper 38788720 Paper 38771177 Paper 38769385 Paper 38759331 Paper 38742743 Paper 38670986 Paper 38650010 Paper 38623754 Paper 38607917 Paper 38569609 Paper 38519039 Paper 38438700 Paper 38380561 Paper 38359680 Paper 38350748 Paper 38325549 Paper 38272925 Paper 38260522 Paper 38260227 Paper 38242440 Paper 38236581 Paper 38226619 Paper 38106038 Paper 38104870 Paper 38104127 Paper 37985794 Paper 37985571 Paper 37922879 Paper 37909039 Paper 37890720 Paper 37884120 Paper 37857141 Paper 37827871 Paper 37772998 Paper 37760589 Paper 37737622 Paper 37697042 Paper 37696029 Paper 37671594 Paper 37655425 Paper 37619838 Paper 37595184 Paper 37588752 Paper 37575220 Paper 37556556 Paper 37543556 Paper 37523502 Paper 37466869 Paper 37460738 Paper 37442696 Paper 37436874 Paper 37350479 Paper 37315312 Paper 37311534 Paper 37307512 Paper 37306774 Paper 37188803 Paper 37182536 Paper 37173865 Paper 37149546 Paper 37009691 Paper 36966348 Paper 36944149 Trial NCT06529120 Trial NCT04576091 Trial NCT02154399 Trial NCT01284010 Trial NCT00890032 Trial NCT00811655 Trial NCT00742625 Trial NCT00626483 Trial NCT00470054 Trial NCT00337194 Trial NCT00118235 Trial NCT00110214 Trial NCT00098670 Trial NCT00086827 Patent 8399434

Abstract

The Functional Genomics (FG) shared resource supports Duke Cancer Institute investigators by providing a broad range of services to facilitate the application of functional genomics and high-throughput screening technologies to the study of cancer. Through investments in CRISPR, RNAi, Open Reading Frame (ORF) and compound collections, as well as high-throughput screening infrastructure, we have assembled stateof- the-art technological platforms for functional studies in both high-and low-throughput applications. The FG provides expertise and assistance in developing and implementing genetic screens in arrayed or pooled format, as well as custom services for the creation of individual knockout, knockin or overexpression cellular models. In addition, FG enables screening of varied compound collections with either cell-based or biochemical assays for chemical genetic or drug discovery studies. FG also provides access to advanced instrumentation for screen-related or standalone assays, including multimodal plate readers and a highcontent screening (HCS) system for image-based analysis. Finally, the FG is dedicated to developing and adapting new techniques and reagents to better support the needs of DCI investigators, enabling them to keep pace with the rapidly evolving field of functional genomics. In 2022, Functional Genomics provided services to 61 DCI investigators, 67% of all users, and represented 6 DCI Research Programs. Use of the shared resource by DCI members contributed to 39 publications over the current project period, demonstrating the value of services offered by this shared resource. The FG shared resource is primarily supported by cost recovery through service fees, with additional institutional support to subsidize operating costs.

View original record on NIH RePORTER →